| Date | Subject | Details |
|---|---|---|
| 2024/04/10 | Announcement Completion of Cancellation of NewlyIssued Restricted Employee Shares and Relevant Changesin Registration | 20240410 |
| 2024/03/29 | The Ministry of Health and Welfare has approvedthe collaborative autologous Gamma-Delta T cell therapyproject by the Company and Chi Mei Hospital, Liouying | 20240329 |
| 2024/03/26 | Taiwan MOHW has approved a new version of thecollaborative autologous Natural Killer cell therapyproject by the Company and Changhua Christian Hospital | 20240326 |
| 2024/03/20 | Taiwan MOHW has approved a New Version of thecollaborative autologous Natural Killer cell therapyproject by the Company and Chi Mei Hospital, Liouying | 20240320 |
| 2024/03/12 | Announcement to explain the difference between thecompany’s consolidated monthly operating incomedeclaration for 12/2024 and accountants audited numbers. | 20240312 |
| 2024/03/11 | Announcement to explain the difference between thecompany’s consolidated monthly operating incomedeclaration for 12/2024 and accountants audited numbers. | 20240311-6 |
| 2024/03/11 | The Board of Directors has resolved not to distributedividends | 20240311-5 |
| 2024/03/11 | The Company’s board of directors resolvedto convene 2024 General Shareholder’s meeting | 20240311-4 |
| 2024/03/11 | Appointment of our company’s new ChiefScientific Officer | 20240311-3 |
| 2024/03/11 | The Company’s Board of Directors has resolvedto redeem and cancel the restricted stocks issued toemployees | 20240311-2 |
| 2024/03/11 | The Company’s 2023 consolidated financialstatements have been approved by the Board of Directors | 20240311-1 |
| 2024/02/29 | Our company has applied to the Taiwan Food and DrugAdministration (TFDA) for Phase I/II clinical trial ofallogeneic natural killer cells (Magicell-NK) | 20240229 |
| 2024/02/16 | The Ministry of Health and Welfare has approved the collaborative autologous Gamma-Delta T cell therapy project by the Company and Changhua Christian Hospital | 20240216 |
| 2024/02/07 | Signing of the sales cooperation agreementfor the new drug OBP-301 in Japan. | 20240207 |
| 2024/01/30 | Announcement of Important Resolutions by the Board of Directors of Our Company | 20240130 |
| 2024/01/11 | Approved the collaborative autologous Gamma-Delta T cell therapy project by the Company and Taichung Tzu Chi Hospital | 20240111 |
